Is IOVA a good stock to buy?

**Iovance Biotherapeutics (IOVA) is not a good stock to buy at this moment**. Here's why:

1. **Recent Performance and Guidance Revision**: Iovance reported second-quarter results below Wall Street's expectations, leading to a significant revision of the company's full-year 2025 guidance. This indicates challenges in meeting financial targets, which could negatively impact investor confidence.
2. **Stock Price Decline and Market Sentiment**: The stock has experienced a significant decline, falling 28% to $1.91 on Friday in early trading, and is down 64% this year. This substantial drop in price and significant market underperformance suggests caution for investors.
3. **Financial Position and Future Outlook**: Iovance's financial position remains a concern, with a reported quarterly loss of $0.33 per share and missing revenue estimates. The company's cash runway is expected to extend into the fourth quarter of 2026, but this is amid a strategic restructuring and cost savings.
4. **Strategic Restructuring and Leadership Transition**: Iovance is implementing a strategic restructuring plan expected to result in more than $100 million in annual cost savings. However, the resignation of the Chief Financial Officer, Jean-Marc Bellemin, amid this turmoil could lead to additional uncertainty.
5. **Legal and Commercial Challenges**: The company is defending against a securities fraud class action related to allegations about its authorized treatment centers (ATCs) and the portrayal of demand for its drug Amtagvi. Commercial setbacks and the slow treatment timelines for new ATCs have contributed to the recent launch dynamics.
6. **Valuation Metrics**: Iovance's P/E ratio is negative at -1.96, indicating that the company is not profitable as currently reported. The P/S ratio is 3.16, which could suggest that the market is currently valuing the company's sales at a premium compared to peers, but this needs to be considered in the context of the company's growth prospects and operational performance.

|code|Ticker|Name|Date|P/E(TTM)|P/S|Price to Book Ratio|market_code|
|---|---|---|---|---|---|---|---|
|IOVA|IOVA.O|Iovance|20240812|-6.807483|48.09618489550925|3.982810715840617|185|
|IOVA|IOVA.O|Iovance|20240813|-7.249615|51.21993314603564|4.241486077156988|185|
|IOVA|IOVA.O|Iovance|20240814|-6.824358|48.21541192797209|3.9926838212343707|185|
|IOVA|IOVA.O|Iovance|20240815|-7.202365|50.886097455139684|4.213841382054475|185|
|IOVA|IOVA.O|Iovance|20240816|-7.087613|50.075353634392386|4.146704265376943|185|
|IOVA|IOVA.O|Iovance|20240819|-7.55337|53.36601973036674|4.419201974244571|185|
|IOVA|IOVA.O|Iovance|20240820|-7.620871|53.8429278602181|4.458694395819589|185|
|IOVA|IOVA.O|Iovance|20240821|-7.985377|56.41823176141542|4.67195347232469|185|
|IOVA|IOVA.O|Iovance|20240822|-7.843625|55.41672468872757|4.58901938701715|185|
|IOVA|IOVA.O|Iovance|20240823|-8.012377|56.60899501335596|4.687750440954697|185|

In conclusion, while Iovance Biotherapeutics has a strong pipeline and therapeutic approach, the current financial, operational, and legal challenges make it a risky investment at this time. Investors should consider these factors and the potential for further stock price volatility before making a decision to buy.